Addressing an Unmet Clinical Need
RCC remains a silent killer in urologic oncology, with over 50% of cases detected incidentally and 30% already metastatic at diagnosis. RCC early detection can significantly improve patients’ survival. While ultrasound is the frontline imaging modality, its sensitivity for detecting small tumors <2 cm) is suboptimal (60%). RED directly addresses this gap by detecting tumor-derived methylation signatures in urine, a non-invasive and easily accessible biofluid, thereby enabling timely intervention when curative treatment is still feasible.
Methodological Rigor and Translational Feasibility
A key challenge in liquid biopsy lies in identifying tumor-derived signals that are both biologically relevant and technically detectable. Our biomarker discovery pipeline integrated multiple datasets of different sample types to ensure biological relevance and clinical applicability. Machine learning (random forest) and PCR design optimization further refined the model to five methylation markers, balancing diagnostic accuracy with technical accessibility. The large-scale multicenter studies validated RED’s robustness, achieving AUCs of 0.81-0.88 with consistent sensitivity (80.7-82.8%) and specificity (75.0-77.1%).
Beyond Sensitivity: RED’s Diagnostic Versatility
RED showed promising potential in detecting small tumors and predicting prognosis:
- RED demonstrated 89.5% sensitivity for tumors <2 cm in diameter, outperforming ultrasound (60% sensitivity for <2 cm), suggesting RED can serve as a promising diagnostic tool in complement to imaging in the clinic
- Survival analysis of TCGA data revealed that low RED risk scores correlate with significantly improved outcomes, suggesting dual utility for diagnosis and risk stratification.
RED requires further validation in larger, prospective cohorts of diverse RC tumor sizes and histology types. Additionally, integrating RED into screening protocols for high-risk populations and exploring its utility in monitoring recurrence could further solidify its clinical role.
Conclusion
RED offers a non-invasive, patient-friendly tool that enables home-based sampling. Its clinical applicability spans screening, diagnosis, and prognostic assessment, enabling a transformative shift in RCC management from incidental discovery to proactive interception, which has the potential to reduce RCC mortality substantially.
Written by: Jian-Bing Fan, PhD, AnchorDx Medical Co., Ltd., Guangzhou, China; Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
Read the Abstract